Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

KalVista Pharmaceuticals (KALV) EBITDA Margin: 2014-2020

Historic EBITDA Margin for KalVista Pharmaceuticals (KALV) over the last 6 years, with Apr 2020 value amounting to -185.25%.

  • KalVista Pharmaceuticals' EBITDA Margin rose 10016.00% to -185.25% in Q2 2020 from the same period last year, while for Apr 2020 it was -229.09%, marking a year-over-year decrease of 9494.00%. This contributed to the annual value of 3,200.86% for FY2025, which is 345501.00% up from last year.
  • As of Q2 2020, KalVista Pharmaceuticals' EBITDA Margin stood at -185.25%, which was up 68.28% from -583.96% recorded in Q1 2020.
  • In the past 5 years, KalVista Pharmaceuticals' EBITDA Margin ranged from a high of 90.77% in Q3 2016 and a low of -93,257.14% during Q1 2016.
  • Over the past 3 years, KalVista Pharmaceuticals' median EBITDA Margin value was -154.02% (recorded in 2019), while the average stood at -188.99%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 2,324,286bps in 2016, then soared by 484,171bps in 2018.
  • Quarterly analysis of 5 years shows KalVista Pharmaceuticals' EBITDA Margin stood at -1,000.00% in 2016, then surged by 55,377bps to -446.23% in 2017, then spiked by 39,060bps to -55.63% in 2018, then tumbled by 8,161bps to -137.24% in 2019, then surged by 10,016bps to -185.25% in 2020.
  • Its last three reported values are -185.25% in Q2 2020, -583.96% for Q1 2020, and -137.24% during Q4 2019.